← back to search

Hans‐Henning Flechtner

Otto-von-Guericke University Magdeburg · DE
Area of research
Oncology · Economics and Econometrics
Research interest
Research interests include Cancer survivorship and care, Health Systems, Economic Evaluations, Quality of Life, Childhood Cancer Survivors' Quality of Life, and Lymphoma Diagnosis and Treatment.
h-index
44
citations
22,044
works
218
NIH funding
primary concept
Medicine
email

Recent publications

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study
eClinicalMedicine 2025cited by 18position: contributordoi
Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study
EClinicalMedicine 2025cited by 15position: middledoi
Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs
European Journal of Cancer 2024cited by 15position: middledoi
[Ethical Considerations of Including Minors in Clinical Trials Using the Example of the Indicated Prevention of Psychotic Disorders].
2024cited by 0position: contributordoi
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types
European Journal of Cancer 2023cited by 166position: middledoi
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
2023cited by 110position: contributordoi
Twice weekly polymerase chain reaction (PCR) surveillance swabs are not as effective as daily antigen testing for containment of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreaks: A modeling study based on real world data from a child and adolescent psychiatry clinic.
2023cited by 1position: contributordoi
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study
European Journal of Cancer 2022cited by 32position: middledoi
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.
2022cited by 21position: contributordoi
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients
Neuro-Oncology 2021cited by 41position: middledoi
Effects of a five-day HD-tDCS application to the right IFG depend on current intensity: A study in children and adolescents with ADHD
Progress in brain research 2021cited by 34position: middledoi
Comparison between conventional and HD-tDCS of the right inferior frontal gyrus in children and adolescents with ADHD
Clinical Neurophysiology 2020cited by 72position: middledoi
Minimally important differences for interpreting the EORTC QLQ‐C30 in patients with advanced colorectal cancer treated with chemotherapy
Colorectal Disease 2020cited by 48position: middledoi
Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
2020cited by 32position: contributordoi
Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer
JNCI Cancer Spectrum 2019cited by 112position: middledoi
Current state of quality of life and patient-reported outcomes research.
2019cited by 94position: contributordoi
Sensitivity to change of the EORTC quality of life module measuring cancer‐related fatigue (EORTC QlQ‐Fa12): Results from the international psychometric validation
Psycho-Oncology 2019cited by 31position: middledoi
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review
The Lancet Oncology 2018cited by 98position: middledoi
Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol
BMJ Open 2018cited by 67position: middledoi
Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma
European Journal of Cancer 2018cited by 61position: middledoi
Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
Clinical Trials 2018cited by 48position: middledoi
Orbitofrontal Signaling of Future Reward is Associated with Hyperactivity in Attention-Deficit/Hyperactivity Disorder
Journal of Neuroscience 2018cited by 28position: middledoi
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
The Lancet Oncology 2016cited by 117position: middledoi
Improving Interference Control in ADHD Patients with Transcranial Direct Current Stimulation (tDCS)
Frontiers in Cellular Neuroscience 2016cited by 104position: middledoi
The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients
European Journal of Cancer 2015cited by 148position: middledoi
The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative
JNCI Journal of the National Cancer Institute 2015cited by 37position: middledoi
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial
British Journal of Cancer 2014cited by 95position: middledoi
Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002
Supportive Care in Cancer 2014cited by 51position: middledoi
A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites
Cancer 2013cited by 202position: middledoi
Development of an EORTC quality of life phase III module measuring cancer‐related fatigue (EORTC QLQ‐FA13)
Psycho-Oncology 2012cited by 74position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Andrew Bottomley · European Organisation for Research and Treatment of Cancer18 papers (2012–2025)Corneel Coens · KU Leuven18 papers (2012–2025)Galina Velikova · University of Leeds12 papers (2015–2025)Jolie Ringash · Princess Margaret Cancer Centre10 papers (2012–2025)Mirjam A. G. Sprangers · Dutch Cancer Society9 papers (2013–2023)Divine Ediebah · University of Regensburg8 papers (2012–2018)Jammbe Musoro · European Organisation for Research and Treatment of Cancer8 papers (2018–2025)Joachim Weis · University of Freiburg8 papers (2012–2019)Chantal Quinten · European Centre for Disease Prevention and Control8 papers (2012–2018)Efstathios Zikos · University of Regensburg7 papers (2012–2015)Francesca Martinelli · University of Perugia7 papers (2012–2025)Mogens Grøenvold · University of Copenhagen7 papers (2018–2025) · 7 papers (2019–2025)Carolyn Gotay · University of British Columbia7 papers (2012–2018) · 6 papers (2012–2018)Bryce B. Reeve · Duke University Health System6 papers (2012–2015)Jaap C. Reijneveld · Academic Medical Center5 papers (2018–2025)Susanne Singer · University Medical Center Freiburg5 papers (2012–2024)Yvonne Brandberg · Karolinska Institutet5 papers (2018–2025)Michael Koller · University Hospital Regensburg4 papers (2018–2025)